I have been a shareholder since June 2013. The first year was great but the last two have really tested my patience despite progress that the company has been making.
Investing in biotech is not for the impatient or those with a short term outlook (less than five years). Like many, I have had visions of the share price popping to $50 or more by 2017. Well, this is not likely to happen because the trials and approval process does take years. And since shorts love volatile stocks and sectors, small biotech companies like Inovio are easily manipulated in the markets, even when there is seemingly
People complain that management does not share enough information with its shareholders. I believe they do not share unless they are required to do so. Too many times I have seen CEOs of other companies tweet and make comments (eg. CNBC) and rarely seen a favorable outcome regarding share price of their company stock.
With the absence of information and long gaps in PRs, an investor has to look at other tangible clues to get
an idea of the confidence that management has in the future. The obvious indicator is employment and Inovio has been growing steadily. The other is insider buying and last I checked there has been some buying by management and very little selling of shares.
Earnings coming up end of month. Look for another quarter of excellent results. This one is headed to $10 in 2017. Not a lot of hype because the climb has been steady without a lot of volatility. Should be back to $3.00 by end of July.
There seems to be little resistance as the company continues to repurchase shares. And it will continue to buy patents and increase revenue. What more could you want?
As predicted, $3 fast approaching. May fall a bit short at the end of May but still on track to hit $5
near next earnings announcement. Watch how this develops as a near perfect run continues.
Company will be repurchasing shares. Dividend still intact. All the bad news has been released. $4.00 is a bargain. Lawsuits will go away as very difficult to prove that the officers of the company did not act with reasonable care, in good faith and reasonable belief that they were acting in the best interests of the company.
These knee jerk lawsuits rarely amount to anything. If you read the conference call transcript, management made a good faith effort to investigate the status of credit card issuers. Willful fraud and/or deception will be hard to prove and each of these lawsuits will eventually be dropped (except that these law firms will not make that announcement and the headlines will remain on the news reel).
It's unfortunate that the stock price took such a hit and may not recover for some time. I would not sell here unless you want to offset capital gains. Once all of the negativity is out, smart investors will see the long-term prospects and view PMTS as a value stock.
Analysts overhyped the company's guidance, not the company. The biggest takeaway is the share repurchase which begins on May 17th. This is huge! Recently, WILN announced share repurchase on Feb. 4th and the stock has risen from $1.21 to $2.58. When management decides to repurchase shares, this is a very positive indicator. I see this rebounding back to $8 in near future. Also, keep in mind that the "misses" were not that dramatic. Company is growing and improving profit margins. The downgrade effect will be short-lived. Watch what happens on May 17th to the stock...the company will not wait to repurchase shares.
The early surge in volume cooled off pretty quickly. Need at least 3x average volume to get on radar. The company will continue to repurchase to boost share price. This could run to $10 without a lot of attention from Wall Street.as long as the gains are methodical and consistent like they have been the past six months.
You must feel good about your ability to uncover my lie. What prompted you to even do the simple research? Did you feel my latest statement was a lie? It's apparent that this faceless message board is where you feel the most comfortable
in stroking your own ego and you are in good company.
We all know that everything written on here has absolutely no impact on the share price of Inovio. We are here to validate our investments with others to feel better about our decisions. This medium is never to be taken seriously and some of us enjoy throwing a few curves just to have a little fun. Why do it? Because we can.
Same here. Began buying in 2013 and held every share. Took advantage of oversold situation in January and picked up a few more shares at $5.00.
Inovio has lots of irons in the fire but needs that one great event that catapults the
stock. A Zika vaccine would produce revenue and visions of $100/sh or $400/sh can only be attained by bringing a product to market, hopefully several cancer vaccines.